ClinicalTrials.gg
TerminatedNCT01738698Updated Jun 22, 2021Results posted

Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia

A Phase 3 interventional study of SPD489 40mg and SPD489 100mg in Schizophrenia, sponsored by Shire. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-22.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.

Enrollment
8th of 11
4 · median 20
Started
2012
with 1 other
Phase 3
4 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Schizophrenia by Takeda, this one is the 8th largest by enrollment, is one of 2 that started in 2012, is one of 4 in phase 3, and was the 4th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →

Where they have run

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Schizophrenia by Takeda as a file.
02

Study summary

The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 65 years of age
  • Has a reliable informant (eg, family member, social worker, caseworker, or nurse that spends >4 hours/week with the subject)
  • Fixed home/place of residence and can be reached by telephone
  • On a stable dose of antipsychotic medications
  • Able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors, modafinil, or other stimulants such as methylphenidate and other amphetamine products
  • Treated with clozapine in past 30 days
  • Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence
  • History of seizures (other than infantile febrile seizures), any tic disorder, or current diagnosis and/or a known family history of Tourette's Disorder, serious neurological disease, history of significant head trauma, dementia, cerebrovascular disease, Parkinson's disease, or intracranial lesions
  • Uncontrolled hypertension
  • History of thyroid disorder that has not been stabilized on thyroid medication
  • Glaucoma
  • Pregnant or nursing
  • Subject has received an product or participated in a clinical study within 30 day
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    SPD489 40mg

    Drug: SPD489 40mg

  • Experimental
    SPD489 100mg

    Drug: SPD489 100mg

  • Experimental
    SPD489 160mg

    Drug: SPD489 160mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral administration of 40 mg once-daily for up to 12 weeks

    Also known as: lisdexamfetamine dimesylate, LDX, Vyvanse

  • Oral administration of 100 mg once-daily for up to 12 weeks

    Also known as: lisdexamfetamine dimesylate, LDX, Vyvanse

  • Oral administration of 160 mg once-daily for up to 12 weeks

    Also known as: lisdexamfetamine dimesylate, LDX, Vyvanse

  • DrugPlacebo

    Oral administration once-daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Negative Symptom Assessment - 16-item (NSA-16) Total Score at 12 Weeks

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change From Baseline in the Personal and Social Performance Scale (PSP) Score at 12 Weeks

    Time frame: Baseline and 12 weeks

  2. Change From Baseline in Simpson Angus Scale (SAS) Total Score at 12 Weeks

    Time frame: Baseline and 12 weeks

  3. Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 12 Weeks

    Time frame: Baseline and 12 weeks

  4. Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 12 Weeks

    Time frame: Baseline and 12 weeks

  5. Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 12 Weeks

    Time frame: Baseline and 12 weeks

  6. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 12 Weeks

    Time frame: Baseline and 12 weeks

  7. Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 12 Weeks

    Time frame: Baseline and 12 weeks

  8. Change From Baseline in Social Functioning Scale (SFS) at 12 Weeks

    Time frame: Baseline and 12 weeks

  9. Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 12 Weeks

    Time frame: Baseline and 12 weeks

  10. Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale

    Time frame: Baseline and week 12

  11. Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale

    Time frame: Up to 12 weeks

  12. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to 12 weeks

  13. Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 12 Weeks

    Time frame: Baseline and 12 weeks

  14. Ambulatory Blood Pressure Monitoring (ABPM)

    Time frame: Baseline and Weeks 4 and 10

07

Results

Posted May 29, 2014
Limitations and caveats
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized

Participant flow

Participant flow — Overall Study
MilestoneSPD489 40mgSPD489 100mgSPD489 160mgPlacebo
Started0000
Completed0000
Not completed0000

Outcome measures

PrimaryChange From Baseline in Negative Symptom Assessment - 16-item (NSA-16) Total Score at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Personal and Social Performance Scale (PSP) Score at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Barnes Akathisia Scale (BAS) Total Score at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cognitive Test Battery (CogState Battery) Score at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Social Functioning Scale (SFS) at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryClinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale
Time frame:
Baseline and week 12

No measurements were reported for this outcome.

SecondaryClinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale
Time frame:
Up to 12 weeks

No measurements were reported for this outcome.

SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)
Time frame:
Up to 12 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 12 Weeks
Time frame:
Baseline and 12 weeks

No measurements were reported for this outcome.

SecondaryAmbulatory Blood Pressure Monitoring (ABPM)
Time frame:
Baseline and Weeks 4 and 10

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489 40mg———
SPD489 100mg———
SPD489 160mg———
Placebo———

Baseline characteristics

Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized

Age, Categorical
Age, CategoricalSPD489 40mgSPD489 100mgSPD489 160mgPlaceboTotal
<=18 years—————
Between 18 and 65 years—————
>=65 years—————
Sex: Female, Male
Sex: Female, MaleSPD489 40mgSPD489 100mgSPD489 160mgPlaceboTotal
Female—————
Male—————
Region of Enrollment
Region of EnrollmentSPD489 40mgSPD489 100mgSPD489 160mgPlaceboTotal
08

Study locations

1 site
  • University Hills Clinical Research
    Irving, Texas 75062, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Apr 2013, 5 months.

Results were first posted in May 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2012
First posted
Nov 30, 2012
StartActual
Nov 1, 2012
Primary completionActual
Apr 1, 2013
CompletionActual
Apr 1, 2013
Results first posted
May 29, 2014
Last update
Jun 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01738698
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Nov 30, 2012
Start date
Nov 1, 2012
Primary completion
Apr 1, 2013
Completion
Apr 1, 2013
Results posted
May 29, 2014
Last update
Jun 22, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion